ATCGrare is available to help with your drug development for rare and genetic diseases. From early clinical development planning to execution of phase 3 studies, we have experience with strategic planning of drug development, clinical trial design, regulatory interactions, and optimizing patient safety during clinical conduct.

Dr. Dan Levy, Founder and Consultant, has extensive experience with evaluation of candidate molecules for treatments of rare disease, including genetic medicines.